No abstract available
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / enzymology*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / pathology
-
Chemotherapy, Adjuvant
-
Female
-
Gene Expression Regulation, Enzymologic
-
Gene Expression Regulation, Neoplastic
-
Heart Failure / chemically induced
-
Humans
-
Immunohistochemistry
-
In Situ Hybridization, Fluorescence
-
Neoadjuvant Therapy
-
Neoplasm Metastasis
-
Observer Variation
-
Patient Selection*
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Receptor, ErbB-2 / analysis*
-
Receptor, ErbB-2 / genetics
-
Reproducibility of Results
-
Trastuzumab
-
Treatment Outcome
-
Up-Regulation
-
Ventricular Dysfunction, Left / chemically induced
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Hormonal
-
Protein Kinase Inhibitors
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
Trastuzumab